GSK Blood Cancer Drug Issues

News

GSK, FDA and Drug Administration

FDA advisers say risks of GSK blood cancer drug outweigh benefits in surprise setback

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the selected dose

· 2d · on MSN

GSK falls as blood cancer drug likely headed for US rejection

· 2d

GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning

STAT2d

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

Wall Street Journal7mon

GSK Gets Positive Results in Blood-Cancer Drug Trial - WSJ

GSK ’s GSK -3.16% blood-cancer drug Blenrep showed positive overall survival data in a late-stage trial, increasing the likelihood for the treatment to return to market next year. The data ...

AOL7mon

GSK's Blood Cancer Drug Shows Improved Survival Compared To ... - AOL

GSK (GSK): Free Stock Analysis Report This article GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex originally appeared on Benzinga.com ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results